Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 2
1992 9
1993 8
1994 5
1995 4
1996 9
1997 7
1998 4
1999 6
2000 8
2001 1
2002 3
2003 6
2004 3
2005 3
2006 8
2007 8
2008 10
2009 5
2010 8
2011 9
2012 9
2013 6
2014 8
2015 9
2016 10
2017 6
2018 10
2019 11
2020 8
2021 6
2022 5
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: zeimet ag. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Clinical Trial.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. Colombo N, et al. Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062. Ann Oncol. 2019. PMID: 31046081 Free article.
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system.
Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, Xiu J, Korn WM, Berger MD, Lenz HJ, Puccini A, Fontana E, Shields AF, Marshall JL, Hall M, El-Deiry WS, Hsiehchen D, Macarulla T, Tabernero J, Pichler R, Khushman M, Manne U, Lou E, Wolf D, Sokolova V, Schnaiter S, Zeimet AG, Gulhati P, Widmann G, Seeber A. Zimmer K, et al. Among authors: zeimet ag. NPJ Precis Oncol. 2023 Jul 3;7(1):64. doi: 10.1038/s41698-023-00409-5. NPJ Precis Oncol. 2023. PMID: 37400502 Free PMC article.
Ovarian Cancer Stem Cell Heterogeneity.
Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG. Hatina J, et al. Among authors: zeimet ag. Adv Exp Med Biol. 2019;1139:201-221. doi: 10.1007/978-3-030-14366-4_12. Adv Exp Med Biol. 2019. PMID: 31134503 Review.
A comparison of four technologies for detecting p53 aggregates in ovarian cancer.
Heinzl N, Koziel K, Maritschnegg E, Berger A, Pechriggl E, Fiegl H, Zeimet AG, Marth C, Zeillinger R, Concin N. Heinzl N, et al. Among authors: zeimet ag. Front Oncol. 2022 Sep 8;12:976725. doi: 10.3389/fonc.2022.976725. eCollection 2022. Front Oncol. 2022. PMID: 36158680 Free PMC article.
210 results